Nyrada Receives A$1.235M R&D Tax Incentive Rebate

Nyrada Inc (ASX:NYR), a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers today announces today announced it has received a A$1,235,480 cash rebate from the Australian Federal Government’s Research & Development (R&D) tax incentive program.